The Operation Eyesight Universal Institute for Eye Cance; The Anant Bajaj Retina Institute, L V Prasad Eye Institute, Hyderabad, Telangana, India.
The Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
Indian J Ophthalmol. 2023 Nov;71(11):3544-3551. doi: 10.4103/IJO.IJO_3325_22.
We evaluated the anatomical and functional outcomes after vitreoretinal surgery for complex retinal capillary hemangioblastoma (RCH).
This was a retrospective case series of 15 patients (16 eyes) with tractional or combined retinal detachment (RD) managed with pars plana vitrectomy and tumor endoresection (ER) with/without feeder vessel ligation.
The mean age at the time of surgery was 30 years (range, 14-46 years). The most common tumor locations were inferotemporal (six eyes) and temporal (six eyes) quadrants. Indications for surgery included exudative RD with fibrovascular proliferation (eight eyes), combined RD (five eyes), vitreous hemorrhage (four eyes), and rhegmatogenous RD (two eyes). Tumor destruction was performed with laser and/or cryotherapy in nine eyes (57%) and ER in seven eyes (43%). Feeder vessel was ligated and cauterized in 10 (63%) and six eyes (37%), respectively. Anatomical success after initial surgery was 50% (eight eyes), which improved to 88% (14 eyes) after they underwent a repeat procedure for recurrent RD (eight eyes). At the last visit, visual acuity improved in seven eyes (44%), was stable in four eyes (25%), and worsened in five eyes (31%) with a mean follow-up of 29 months (6-79 months). Comparison between the ER group and the laser/cryotherapy group revealed no significant difference in final retinal reattachment rate (89% vs. 86%, P > 0.05), with better visual outcomes in laser/cryotherapy group (57% vs. 78%, P < 0.05).
Pars plana vitrectomy with/without tumor endoresection can be a safe and effective treatment option for complex RCHs, achieving good tumor control and anatomical success with limited functional success.
评估视网膜毛细血管血管瘤(RCH)行玻璃体视网膜手术后的解剖和功能结果。
本研究回顾性分析了 15 名(16 只眼)患有牵拉性或合并性视网膜脱离(RD)的患者,这些患者均接受了经睫状体平坦部玻璃体切除术联合肿瘤内切除术(ER)治疗,其中部分患者联合了滋养血管结扎。
手术时的平均年龄为 30 岁(14-46 岁)。最常见的肿瘤部位是下颞(6 只眼)和颞侧(6 只眼)象限。手术指征包括渗出性 RD 伴纤维血管增生(8 只眼)、合并性 RD(5 只眼)、玻璃体积血(4 只眼)和孔源性 RD(2 只眼)。9 只眼(57%)采用激光和/或冷冻治疗破坏肿瘤,7 只眼(43%)行 ER。分别有 10 只眼(63%)和 6 只眼(37%)结扎和电凝滋养血管。初次手术后解剖复位率为 50%(8 只眼),在因复发性 RD 行重复手术后提高至 88%(14 只眼)。末次随访时,7 只眼(44%)视力改善,4 只眼(25%)视力稳定,5 只眼(31%)视力恶化,平均随访时间为 29 个月(6-79 个月)。ER 组与激光/冷冻组最终视网膜复位率无显著差异(89%vs.86%,P>0.05),但激光/冷冻组视力更好(57%vs.78%,P<0.05)。
经睫状体平坦部玻璃体切除术联合或不联合肿瘤内切除术是治疗复杂 RCH 的一种安全有效的治疗方法,可实现良好的肿瘤控制和解剖复位,但功能改善有限。